Study on the mechanism of "Ligusticum chuanxiong Hort.-Salvia miltiorrhiza" couplet medicine for coronary heart disease based on network pharmacology

• 作者: Wen-Qing Ren Shi-Liang Zhang
• 来源期刊: 海南医科大学学报（英文版）
• 年，卷（期）: 2021,（17）
• 所属期刊栏目: Original article
• 页码范围: 31-38
• 页数: 8页
• 语种: 英文

摘要

Objective: To study the active components and gene targets of "Ligusticum chuanxiong Hort.-Salvia miltiorrhiza"couplet medicine for the treatment of coronary heart disease(CHD) based on network pharmacology, and to explore its mechanism. Methods: Based on oral bioavailability(OB)>30％ and drug-like(DL)>0.18,the active components of "Ligusticum chuanxiong Hort.-Salvia miltiorrhiza"for CHD were screened and the targets of treating CHD were predicted by using TCMSP and GeneCards database. The active component-CHD target network was established by Cytoscape 3.7.2 software. The protein-protein interaction(PPI) network was constructed by utilizing String database. Finally,GO enrichment analysis and KEGG pathway enrichment analysis were performed by using Bioconductor and R language. Results: The study predicted 72 active components in total,including 7 Ligusticum chuanxiong Hort. and 65 Salvia miltiorrhiza,such as β-sitosterol, tanshinone. Totally 96 target genen of active components were obtained,including PTGS1,NCOA2,NOS2,etc. Results of GO enrichment analysis showed 142 biological processes,related to adrenergic receptor activity, G protein-coupled amine receptor activity,etc. KEGG pathway enrichment analysis showed 131 pathways,including PI3K-Akt signaling pathway, IL-17 signaling pathway, HIF-1 signaling pathway,etc. Conclusion: "Ligusticum chuanxiong Hort.-Salvia miltiorrhiza"couplet medicine exerts therapeutic effects on CHD from multiple targets as PTGS1,PTGS2 and adrenergic receptor activity and PI3K-Akt signaling pathway. The study can provide reference for further researches on its mechanism and the pharmacological effects of Shenzhi Tongxin Capsule.